Lichen sclerosus et atrophicus-like graft-versus-host disease post stem cell transplant.
A major complication following hematopoietic stem cell transplantation is graft versus host disease. Cutaneous manifestations of chronic graft versus host disease (cGVHD) are varied and this condition impacts patient outcomes and quality of life. We describe two cases of lichen sclerosus et atrophicus-like cGVHD developing in patients after hematopoietic stem cell transplantation. Both patients presented clinically with patches of pigmentary changes and scaling that displayed classic histologic features of lichen sclerosus et atrophicus. The skin is a frequent target organ of cGVHD and often the presenting location of the disease, making dermatologists key in recognition and management. It has been proposed that cutaneous cGVHD is a spectrum of disease and the lesions may evolve through various stages. Lichen sclerosus et atrophicus-like cGVHD may represent a phase in this continuum or a distinct sub-type of disease. Remaining cognizant of the potential manifestations of disease is key for prompt recognition and proper treatment.
Weinberg
Jennifer L
JL
University of Pennsylvania School of Medicine, USA. jenniflw@mail.med.upenn.edu
Rosenbach
Misha
M
Kim
Ellen J
EJ
Kovarik
Carrie L
CL
D002990:Clobetasol / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015473:Leukemia, Promyelocytic, Acute / Q000532:radiotherapy / Q000601:surgery; D018459:Lichen Sclerosus et Atrophicus / Q000175:diagnosis*; D017710:Lymphocyte Transfusion / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D017893:Photopheresis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000601:surgery; D016559:Tacrolimus / Q000627:therapeutic use; D014221:Triamcinolone / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D014221:Triamcinolone; D002990:Clobetasol; D006854:Hydrocortisone; D016559:Tacrolimus